QUTENZA (capsaicin), local analgesic patch
PAIN - Update
Opinions on drugs - Posted on Mar 29 2017
Reason for request
Re-assessment of the actual benefit and the improvement in actual benefit
- QUTENZA is a transdermal system with Marketing Authorisation in the treatment of peripheral neuropathic pain in adults, either alone or in combination with other analgesics.
- Its efficacy is limited and its use is commonly associated with painful reactions at the application site.
- QUTENZA is a second-line and beyond treatment, in combination with other analgesics, in the management of local, evaluable and delimited peripheral neuropathic pain in nondiabetic adults.
- It should be prescribed after consultation with a pain specialist and its use must be re-evaluated regularly due to questions relative to its long-term use (maintenance of efficacy and absence of altered perception).
Clinical Added Value
|no clinical added value||
Évaluation des médicaments